All In Biotech

Drug Trial Radar · NCT02351973

Comparison of Single and Combination Diuretics in Low-Renin Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 423 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

423

Actual

Start

Nov 2009

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
University of CambridgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Leicester; University of Dundee; University of Glasgow; University of Edinburgh; Imperial College London; Barts & The London NHS Trust; King's College London; University of Birmingham
First posted
Jan 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the routine combination of optimal thiazide and K+-sparing diuretic will both increase efficacy of BP reduction and reduce risk of glucose intolerance; and whether K+-sparing diuretics alone may have a neutral or even beneficial effect upon glucose tolerance.

Conditions

  • Hypertension

Interventions

  • HydrochlorthiazideDrug

    HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.

  • AmilorideDrug

    Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.

  • Hydrochlorthiazide and AmilorideDrug

    HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood glucose measured two hours after oral ingestion of a 75 G glucose drink, following overnight fasting.Time frame: 0, 12 and 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.